MAPLIGHT THERAPEUTICS INC (MPLT)
Health Care · Clinical-stage biopharmaceuticals · NASDAQ
A clinical-stage biopharmaceutical company advancing novel therapeutic candidates through preclinical and clinical development toward regulatory approval.
What MAPLIGHT THERAPEUTICS INC does
MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutic candidates. The company is advancing preclinical studies and clinical trials for product candidates, with an emphasis on identifying patients and expanding the scope of potential indications for its pipeline. MapLight is pursuing regulatory approvals and commercialization strategies for its therapeutic programs.
Themes: ["clinical-stage biopharmaceuticals","drug discovery and development","regulatory pathway planning"]
Fundamentals
- Price$39.80 as of 2026-07-09 close
- Market cap$1.6B as of 2026-07-10
- 1-year return+119.4% as of 2026-07-09 close
- ROE-35.2% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta1.37 as of 2026-07-10
Key risks (from latest filing)
["Timing, progress and results of preclinical studies and clinical trials are uncertain and may be materially delayed or fail to demonstrate efficacy","Ability to identify and enroll sufficient patients in trials, as well as identify suitable patient populations for product candidates, is not assured","Dependence on existing cash and investments to fund operations; additional capital raising may be necessary and may be dilutive to shareholders"]
Competitors & peers
- Novartis
- Roche
- Merck
- Pfizer
- AbbVie
- Bristol Myers Squibb
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.